Jean-Pierre Sommadossi
CIK 1296995 · President, CEO, and Chairman · last filed 2026-02-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$32.97M
Companies
3
Total Filings
22
Lifetime Open-Market Net
-$457.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVIR | President, CEO, and Chairman | 6,439,948 | $5.12 | $32.97M | -$457.0K | 9 | 2026-02-03 |
| Kezar Life Sciences, Inc. (KZR) Delisted | Director | 14,318 | $7.29 | $104.4K | $0 | 4 | 2021-06-30 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | President, CEO, Chairman | 2,219,754 | — | — | $0 | 7 | 2010-02-11 |
Recent Filings · Page 2 of 3
22 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-02-01 | AVIR | Grant (A) | — | $0 | EDGAR |
| 2020-11-03 | AVIR | Conv (C) | +750,000 | $0 | EDGAR |
| 2020-06-26 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-27 | Kezar Life Sciences, Inc. (KZR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-27 | Kezar Life Sciences, Inc. (KZR) Delisted | Conv (C) | +87,839 | $0 | EDGAR |
| 2010-02-11 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-02-18 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-09-17 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Other (J) | −110,000 | -$880.0K | EDGAR |
| 2008-02-26 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-11-14 | IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.